Camp4 Therapeutics Corporation/$CAMP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Camp4 Therapeutics Corporation
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.
Ticker
$CAMP
Sector
Primary listing
Employees
48
Headquarters
Website
CAMP Metrics
BasicAdvanced
$215m
-
-$2.17
-
-
Price and volume
Market cap
$215m
52-week high
$7.75
52-week low
$1.31
Average daily volume
110k
Financial strength
Current ratio
6.148
Quick ratio
5.968
Long term debt to equity
5.624
Total debt to equity
6.867
Profitability
EBITDA (TTM)
-50.294
Gross margin (TTM)
-871.43%
Net profit margin (TTM)
-2,193.72%
Operating margin (TTM)
-1,322.62%
Revenue per employee (TTM)
$80,000
Management effectiveness
Return on assets (TTM)
-38.66%
Return on equity (TTM)
-209.28%
Valuation
Price to revenue (TTM)
41.909
Price to book
6.96
Price to tangible book (TTM)
6.96
Price to free cash flow (TTM)
-6.281
Free cash flow yield (TTM)
-15.92%
Free cash flow per share (TTM)
-0.659
Growth
Revenue change (TTM)
160.53%
Earnings per share change (TTM)
-59.77%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs